Endosomal Escape Vehicle (EEV™) Platform for Delivery of Oligonucleotides in Duchenne Muscular Dystrophy

Nerissa Kreher, MD, MBA

Chief Medical Officer

Entrada Therapeutics, Inc.

WANT TO LEARN MORE?

Scan the QR code for access to our recent publications and conference presentations.

DISCLAIMER

This presentation includes express and implied “forward-looking statements. Forward looking statements include all statements that are not historical facts, and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained in this presentation include, but are not limited to, statements about our product development activities and clinical trials, our regulatory filings and approvals, our ability to develop and advance our current and future product candidates and discovery programs, our ability to establish and maintain collaborations or strategic relationships or obtain additional funding, the rate and degree of market acceptance and clinical utility of our product candidates, the ability and willingness of our third-party collaborators to continue research and development activities relating to our product candidates, our and our collaborators’ ability to protect our intellectual property for our products. By their nature, these statements are subject to numerous risks and uncertainties, including factors beyond our control, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact.

Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party studies, publications, surveys and other data to be reliable as of the date of this presentation, it has not independently verified, and makes no representations as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research.

WHO WE ARE

Our Commitment

- Developing treatments for people living with serious diseases for which no or insufficient options currently exist
- Partnering with patient communities to ensure the perspectives of patients and their loved ones inform our research programs

Our Culture

- We are building a company culture where everyone can belong, contribute and grow
- Fostering a workplace environment that embraces diversity, equity and inclusion
- Prioritizing the experiences and perspectives of patients and their loved ones

Our Team

- ~130 employees with an experienced leadership team
- Recognized as a Top Place to Work by *The Boston Globe* and *BioSpace*
- Our team mirrors patient populations: 52% of our employees identify as women and 50% as racially or ethnically diverse

OUR COMMITMENT TO THE DUCHENNE COMMUNITY

Our partnerships with community leaders and patient advocacy organizations are at the heart of our work to bring innovative therapies to people living with devastating diseases

We appreciate the Duchenne community's deep experience participating in clinical trials and the work you have done to create a collaborative environment that is welcoming to novel research

As we progress our Duchenne franchise from the lab to the clinic, we look forward to learning from the experiences of people and families living with Duchenne and to keeping you informed of our progress

PURSUING TREATMENT OPTIONS FOR PEOPLE LIVING WITH DUCHENNE

- ENTR-601-44 is a potential approach to treating individuals with Duchenne who are **exon 44 skipping amenable**
- Input from the Duchenne community guided our decision to select our first clinical candidate
- ENTR-601-45 is a potential approach to treating individuals with Duchenne who are **exon 45 skipping amenable**
- Discovery efforts underway for individuals with **exon 50 and 51 amenable mutations**

INTRACELLULAR THERAPEUTICS MAY PRESENT A SOLUTION

Approximately 75% of all disease-causing targets are within the cell and difficult to reach, representing a significant challenge when developing effective therapies





The Endosomal Escape Vehicle (EEV™) Platform aims to solve fundamental problems relating to the inability of medicines to: 1) enter the cell and 2) avoid the cell's natural clearing systems

OUR ENDOSOMAL ESCAPE VEHICLE (EEV™) PLATFORM

We are developing EEV-oligonucleotide conjugates for the treatment of Duchenne

- EEV-oligonucleotide conjugates are cyclic peptides attached to oligonucleotides
- This unique chemistry results in **improved uptake into the cell and escape from the endosome** (the cell's natural clearing system)
- The cyclic structure of the peptide is designed to **extend half life and increase stability**
- In animal studies, we have observed that our EEV-oligonucleotide approach has **promoted enhanced exon skipping and dystrophin production**



Qian, Z. et al. *ACS Chem. Biol.* 2013; Qian, Z. et al. *Biochemistry* 2014; Qian, Z. et al. *Biochemistry* 2016; Sahni, A. et al. *ACS Chem. Biol.* 2020; Pei, D. *Acc. Chem. Res.* 2022.

ENTR-601-44 IS OUR EXON 44 SKIPPING CLINICAL CANDIDATE

A single IV dose of ENTR-601-44 resulted in robust exon skipping in both skeletal and cardiac muscles in non-human primates (NHP), as well as prolonged duration of effect for at least 12 weeks

Exon Skipping in Muscles at Day 7



- 7 days after an intravenous (IV) infusion of 30 mg/kg (PMO equivalent), robust exon 44 skipping observed across different muscle groups isolated from the ENTR-601-44 treated NHP

Duration of Effect in Biceps for at Least 12 Weeks



- After an intravenous (IV) infusion of 35 mg/kg (PMO equivalent), robust exon 44 skipping observed in biceps in the ENTR-601-44 treated NHP (n=3 per cohort) for at least 12 weeks

NHP, non-human primates; Data shown as mean ± standard deviation.

PRECLINICAL DATA SUPPORT ADVANCEMENT OF ENTR-601-44 TO THE CLINIC

Results show:

Effective exon skipping seen in skeletal, diaphragm and heart muscles in animal models

Robust dystrophin production observed in skeletal muscle cells from patients living with Duchenne

Prolonged duration of effect, which may translate to administration of drug up to every 6 weeks

We are developing **ENTR-601-44** for the potential treatment of the roughly 7.5% of individuals with Duchenne who are **exon 44 skipping amenable**

*Following regulatory feedback and potential IND clearance.

ENTR-601-45 EFFECTIVE IN SKELETAL AND CARDIAC MUSCLE CELLS

ENTR-601-45 showed robust exon skipping and dystrophin production in skeletal and cardiac muscle cells from patients living with Duchenne who are amenable to exon 45 skipping

ENTR-601-45 in Skeletal Muscle Cells



- Skeletal muscle cells from patients living with Duchenne who are amenable to exon 45 skipping were treated with ENTR-601-45 for 24 hours and analyzed 5 days later

ENTR-601-45 in Cardiac Muscle Cells



- Cardiac muscle cells from patients living with Duchenne who are amenable to exon 45 skipping were treated with ENTR-601-45 for 24 hours and analyzed 48 hours later

DMDΔ46-48 iPSC-derived skeletal and cardiac muscle cells from an exon 45 skip amenable DMD patient harboring an exon 46-48 deletion mutation. Data are shown as mean ± SD (n = 3 skeletal muscle; n = 4 cardiac muscle); one-way ANOVA; *p<0.05, ****p<0.0001; relative to untreated DMDΔ46-48 cells.

IN SUMMARY

Entrada lead programs are advancing new therapeutic options for people living with exon 44 and exon 45 skip amenable Duchenne

- **ENTR-601-44 produced robust exon skipping and dystrophin production in cell and animal models of Duchenne**
  - We observed robust exon skipping over 12+ weeks from a single injection of ENTR-601-44 in non-human primates
  - Entrada received a clinical hold notice from the FDA regarding our investigational new drug (IND) application for ENTR-601-44 in December 2022
  - Entrada plans to share additional updates pending further communications with the Agency
- **ENTR-601-45 IND filing is planned for H2 2024**
  - ENTR-601-45 showed robust exon skipping and dystrophin production in cardiac and skeletal muscle cells from people living with Duchenne
  - High levels of exon skipping were measured in hDMD mouse heart and skeletal muscle
- **Discovery efforts underway for individuals with exon 50 and 51 amenable mutations**

THANK YOU FROM OUR WHOLE TEAM

Please visit us during the exhibitor showcase later this afternoon!

WANT TO LEARN MORE?

Scan the QR code for access to our recent publications and conference presentations.

For questions, contact:
Regan Sherman, Head of Patient Advocacy, rsherman@entradatx.com